Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind and Placebo-controlled Single Ascending-dose Phase I Study (First-in-human) to Investigate the Safety, Tolerability and Pharmacokinetics of Contraloid Acetate (in Healthy Subjects)

Next Previous
Trial Profile

A Randomized, Double-blind and Placebo-controlled Single Ascending-dose Phase I Study (First-in-human) to Investigate the Safety, Tolerability and Pharmacokinetics of Contraloid Acetate (in Healthy Subjects)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Contraloid (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 31 Jul 2020 Results (n=63) from NCT03944460 and NCT03955380 assessing safety of PRI-002 in healthy volunteers, presented at the Alzheimer's Association International Conference 2020
  • 16 May 2019 New trial record
  • 15 May 2019 According to a Heinrich Heine University Dusseldorf media release, the SAD stage was finished in July 2018, and MAD stage was completed in April 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top